Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusinessMarkets

Sequent Scientific climbs 4% on EIR from USFDA for Bengaluru laboratory

The Bengaluru laboratory was set up in 2017 to cater to the growing analytical requirements of large pharmaceutical and FMCG majors in the region.

August 20, 2019 / 01:38 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Shares of Sequent Scientific, which operates in animal health (Alivira) and analytical services, gained 3.6 percent intraday on August 20 after the company received Establishment Inspection Report for its Analytical Laboratory at Bengaluru.

The stock rallied 48 percent in last one year. It was quoting at Rs 71, up Rs 1.35, or 1.94 percent on the BSE at 1257 hours IST.

"Wholly owned subsidiary Sequent Research Limited (SRL) has received Establishment Inspection Report (EIR) from US Food and Drug Administration for its state-of-the-art GLP compliant, analytical services laboratory at Bengaluru," company said in its BSE filing.

The Bengaluru laboratory was set up in 2017 to cater to growing analytical requirements of large pharmaceutical and FMCG majors in the region.

SRL also has another US FDA approved analytical laboratory at Mangaluru, which has been providing services since 2008, Sequent said.

The Mangaluru laboratory was successfully inspected by the US FDA in December 2018.

SRL is an ISO 17025 certified facility approved by major regulatory authorities including USFDA and operates out of two centres of excellence – Bengaluru and Mangaluru with a team of nearly 100 scientists.

Moneycontrol News
first published: Aug 20, 2019 01:38 pm

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347